Sentence: High-risk node-negative or low-risk node-positive breast cancer patients received AC given : ( arm I ) concurrently ( AC ) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously ( IV ) every 3 weeks for six cycles ; or ( arm II ) in sequence ( A C ) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['doxorubicin', 'cyclophosphamide'], 'is_context_needed': True}, {'class': 'COMB', 'spans': [2, 3], 'is_context_needed': True}]